Citations

Clear

2117 citation(s) found for "Mayo, Steven".

IN REPLY
Ellis, Lee M. , Curley, Steven A. , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | May 31, 2006 | Volume: 24 | Issue: 16 | Pages: 2593-2594

10.1200/jco.2006.05.6515 Get It

Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit.
Ohno, Kinji , Hutchinson, David, Milone, Margherita , Brengman, Joan M., Sine, Steven M. , Engel, Andrew G. , Bouzat, Cecilia

Mayo Clinic

Proceedings of the National Academy of Sciences | May 31, 2006 | Volume: 92 | Issue: 3 | Pages: 758-762

10.1073/pnas.92.3.758 | PMID 7531341 Get It

In a congenital myasthenic syndrome with a severe endplate myopathy, patch-clamp studies revealed markedly prolonged acetylcholine receptor (AChR) channel openings. Molecular genetic analysis of AChR subunit genes demonstrated a heterozygous adenosine-to-cytosine transversion at nucleotide 790 in exon 8 of the epsilon-subunit gene, predicting substitution of proline for threonine at codon 264 and no other mutations in the entire coding sequences of genes encoding the alpha, beta, delta, and epsilon subunits. Genetically engineered mutant AChR expressed in a human embryonic kidney fibroblast cell line also exhibited markedly prolonged openings in the presence of agonist and even opened in its absence. The Thr-264-->Pro mutation in the epsilon subunit involves a highly conserved residue in the M2 domain lining the channel pore and is likely to disrupt the putative M2 alpha-helix. Our findings indicate that a single mutation at a critical site can greatly alter AChR channel kinetics, leading to a congenital myasthenic syndrome. This observation raises the possibility that mutations involving subunits of other ligand-gated channels may also exist and be the basis of various other neurologic or psychiatric disorders.
Role of the Nijmegen Breakage Syndrome 1 Gene in Familial and Sporadic Prostate Cancer
Hebbring, Scott J. , Fredriksson, Henna, White, Kirsten A. , Maier, Christiane, Ewing, Charles M., McDonnell, Shannon K. , Jacobsen, Steven J. , Cerhan, James R. , Schaid, Daniel J. , Ikonen, Tarja, Autio, Ville, Tammela, Teuvo L.J. , Herkommer, Kathleen , Paiss, Thomas, Vogel, Walther , Gielzak, Marta, Sauvageot, Jurga, Schleutker, Johanna , Cooney, Kathleen A. , Isaacs, William B. , Thibodeau, Stephen N. , Cerhan, James R , Schleutker, Johanna , McDonnell, Shannon K

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 15, 2006 | Volume: 15 | Issue: 5 | Pages: 935-938

10.1158/1055-9965.epi-05-0910 | PMID 16702373 Get It

Abstract The Nijmegen breakage syndrome 1 (NBS1) gene, which participates in DNA double strand break repair, has been postulated to be a susceptibility factor for a number of cancers, including prostate cancer. Numerous mutations have been identified in NBS1, including the founder mutation 657del5. In this study, a number of analyses were done to determine whether mutations in NBS1 are associated with an increased risk for prostate cancer. The frequency of the 657del5 mutation in both familial prostate cancer cases (1,819 affected men among 909 families) and sporadic prostate cancer cases (1,218 affected men) collected from five centers participating in the International Consortium for Prostate Cancer Genetics were compared with that found in 697 normal controls. Seven individuals were identified to carry the mutation among the 3,037 cases screened: four in the familial group (three from one family and one from another) and three in the sporadic cases. The carrier frequency was 0.22% (2 of 909) for the probands and 0.25% (3 of 1,218) for the sporadic cases of prostate cancer. The 657del5 mutation was not detected in either the 293 unaffected members of the prostate cancer families or in the 697 control samples tested. The entire NBS1 gene was also sequenced in 20 of the youngest affected individuals from the Finnish group of familial cases to identify the presence of possible mutations in this high-risk group. One rare (D95N) and one common (E185Q) missense alteration was identified. More detailed analyses of the E185Q polymorphism, along with a third rare variant (R215W), failed to show an association with prostate cancer. Because the 657del5 mutation was absent from the control population, we are unable to determine if this alteration predisposes to prostate cancer. However, our data does suggest that mutations within NBS1, and in particular, 657del5, do not significantly contribute to the overall prostate cancer burden within our patient samples. (Cancer Epidemiol Biomarkers Prev 2006;15(5):935–8)
Secular Trends in Deaths From Cardiovascular Diseases
Gerber, Yariv , Jacobsen, Steven J. , Frye, Robert L. , Weston, Susan A., Killian, Jill M. , Roger, Véronique L.

Mayo Clinic

Circulation | May 8, 2006 | Volume: 113 | Issue: 19 | Pages: 2285-2292

10.1161/circulationaha.105.590463 | PMID 16682616 Get It

Background— Although age-adjusted cardiovascular disease (CVD) mortality has declined over the past decades, controversies remain about whether this trend was similar across locations of death and disease categories and about the existence of age and sex disparities. Methods and Results— We examined CVD mortality trends in Olmsted County, Minnesota, between 1979 and 2003 using the categories defined by the American Heart Association, including coronary heart disease (CHD), non-CHD diseases of the heart, and noncardiac circulatory diseases. Data on demographics, cause, and location of death of all 6378 residents who died of CVD were analyzed. Although decreases in the age-adjusted rates occurred in all groups, the magnitude of the decline varied widely. Lesser annual declines were noted in out-of-hospital than in-hospital deaths (1.8% versus 4.8%; P <0.001), in older than in younger persons (1.5% at age ≥85 years versus 3.9% for those ≤74 years of age; P <0.001), and in women relative to men (2.5% versus 3.3%; P =0.007). Furthermore, although CHD showed a marked annual decrease (3.3%), more modest decrements were found for non-CHD diseases of the heart (2.1%) and noncardiac circulatory diseases (2.4%) ( P =0.02 and P =0.04 for the comparison with CHD decline, respectively). Conclusions— Over the past 25 years, CVD mortality declined markedly in the community, but there were large disparities in the magnitude of the decline, resulting in a shift in the distribution toward out-of-hospital and non-CHD deaths. Further reduction in CVD mortality will require strategies directed at elderly persons and women, in whom out-of-hospital rates have improved only minimally.
Female Urology
Petrou, Steven P.

Mayo Clinic

International braz j urol | April 28, 2006 | Volume: 32 | Issue: 1 | Pages: 119-121

10.1590/s1677-55382006000100025 Get It

Female Urology
Petrou, Steven P.

Mayo Clinic

International braz j urol | April 19, 2006 | Volume: 31 | Issue: 6 | Pages: 610-612

10.1590/s1677-55382005000600022 Get It

Orthotopic ureterocele masquerading as a bladder tumor in a woman with pelvic pain
Thiel, David D. , Petrou, Steven P. , Broderick, Gregory A.

Mayo Clinic

International braz j urol | April 19, 2006 | Volume: 31 | Issue: 6 | Pages: 549-551

10.1590/s1677-55382005000600006 | PMID 16386123 Get It

Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide
Rodeheffer, Richard J. , Cataliotti, Alessandro , Martín, Fernando L., Urban, Lynn H., Jacobsen, Steven J. , Redfield, Margaret M. , Burnett, John C. , McKie, Paul M. , Mahoney, Douglas W.

Mayo Clinic

Hypertension | April 3, 2006 | Volume: 47 | Issue: 5 | Pages: 874-880

10.1161/01.hyp.0000216794.24161.8c | PMID 16585413 Get It

Recent studies report that, in the absence of heart failure and renal failure, plasma B-type natriuretic peptide (BNP) has prognostic value for mortality. We sought to confirm and extend these previous studies to assess BNP, measured by 3 distinct assays, as a biomarker for mortality in a strategy to enhance efforts at primary prevention and to better understand the clinical phenotype of such subjects at risk. We used a community-based cohort of 2042 subjects from Olmsted County, Minn, and individuals with heart or renal failure were excluded. BNP was assessed using 3 assays including Biosite and Shionogi for mature, biologically active BNP and the Roche assay for apparently nonbiologically active amino-terminal pro-BNP (NT-proBNP). Thorough echocardiographic and clinical data were recorded for all of the participants. Median follow-up for mortality was 5.6 years. BNP by all 3 of the assays was predictive of mortality. NT-proBNP and Biosite assays remained significant even after adjustment for traditional clinical risk factors and echocardiographic abnormalities including left ventricular hypertrophy and diastolic dysfunction. Echocardiography documented widespread structural changes in those with increasing BNP levels yet below levels observed in heart failure. We report in a large, well-characterized community-based cohort, free of heart failure, the first study to compare 3 distinct BNP assays as biomarkers for mortality in the same cohort. Our findings confirm the potential use of NT-proBNP and BNP biomarkers for future events and underscore that these peptides may also serve as biomarkers for underlying cardiac remodeling secondary to diverse cardiovascular disease entities.
Use of Intermittent Pneumatic Compression for Treatment of Upper Extremity Vascular Ulcers
Pfizenmaier, David H., Kavros, Steven J., Liedl, David , Cooper, Leslie T. , Cooper, Leslie T

Mayo Clinic

Angiology | March 31, 2006 | Volume: 56 | Issue: 4 | Pages: 417-422

10.1177/000331970505600409 | PMID 16079925 Get It

Ischemic vascular ulcerations of the upper extremities are an uncommon and frequently painful condition most often associated with scleroderma and small vessel inflammatory diseases. Digital amputation has been advocated as primary therapy because of the poor outcome with medical care. Intermittent pneumatic compression (IPC) pump therapy can improve ulcer healing in lower extremity ischemic ulcerations; however, the value of this treatment in upper extremity ischemic ulcerations is not known. This observational pilot study consisted of a consecutive series of 26 patients with 27 upper extremity ischemic vascular ulcers seen at the Mayo Gonda Vascular Center from 1996 to 2003. Inclusion criteria were documented index of ulcer size and follow-up ulcer size and use of the IPC pump as adjunctive wound treatment. Twenty-six of 27 ulcers (96%) healed with the use of the IPC pump. Mean baseline ulcer size was 1.0 cm 2 (SD=0.3 cm 2 ) and scleroderma was the underlying disease in 65% (17/26) of cases. Laser Doppler blood flow in the affected digit was 7 flux units (normal greater than 100). The mean ulcer duration before IPC treatment was 31 weeks. The average pump use was 5 hours per day. The mean time to wound healing was 25 weeks. Twenty-five of 26 patients reported an improvement in wound pain with pump use. Intensive IPC pump use is feasible and associated with a high rate of healing in upper extremity ischemic ulcers. A prospective, randomized, sham-controlled study of IPC is needed to determine whether IPC treatment improves wound healing compared to standard medical care.
Phase III Study of Two Different Dosing Schedules of Erythropoietin in Anemic Patients With Cancer
Steensma, David P. , Molina, R, Sloan, Jeff A. , Nikcevich, Daniel A., Schaefer, Paul, Rowland, Kendrith M. , Dentchev, Todor, Novotny, Paul J. , Tschetter, Loren K., Hogan, Thomas F., Law, Amy , Loprinzi, Charles L. , Alberts, Steven R. , Steensma, David P

Mayo Clinic

Journal of Clinical Oncology | February 28, 2006 | Volume: 24 | Issue: 7 | Pages: 1079-1089

10.1200/jco.2005.02.7276 | PMID 16505427 Get It

Purpose To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia. Patients and Methods Eligible patients were randomly assigned at enrollment to receive three weekly doses of epoetin alfa 40,000 U subcutaneously (SC), followed by either standard weekly epoetin alfa (40K arm) or 120,000 U of epoetin alfa (120K arm) SC every 3 weeks for 18 additional weeks. Results Three hundred sixty-five patients were enrolled. One hundred eighty-three patients were assigned to the 40K arm, and 182 were assigned to the 120K arm. There was no difference in the proportion of patients requiring transfusions during the study (23% in 40K arm and 18% in 120K arm, P = .22) or specifically during the maintenance phase (13% in 40K arm v 15% in 120K arm, P = .58). Patients randomly assigned to the 40K arm were more likely to have a ≥ 2 or ≥ 3 g/dL hemoglobin (Hb) increment, were more likely to have a drug dose held because of high Hb, and had higher mean end-of-study Hb levels. Toxicities, including thromboembolism, and overall survival were similar. Patients in the 40K arm had a higher global quality of life (QOL) at baseline for unclear reasons, whereas patients in the 120K arm had a greater global QOL improvement during the study, so end-of-study QOL was equivalent. Conclusion After three weekly doses of epoetin alfa 40,000 U, a dose of 120,000 U can be administered safely once every 3 weeks without increasing transfusion needs or sacrificing QOL. The Hb increment is somewhat greater with continued weekly epoetin alfa. Lack of blinding as a result of different treatment schedules may have confounded results.